Glenmark Pharma Announcements
Report of Scrutinizer and Voting Result under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is enclosed.
26 Sep, 2025 | 07:09pm • Source: BSE
Proceedings of the 47th AGM of the Company is enclosed.
26 Sep, 2025 | 07:02pm • Source: BSE
Glenmark Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on September 26, 2025, declared Interim Dividend of 2.5 per...
26 Sep, 2025 | 11:38am • Source: NSE
Please refer enclosed file.
26 Sep, 2025 | 11:04am • Source: BSE
The Board approved Interim Dividend of Rs. 2.50 per equity shares on face value of Re. 1/- per equity shares for the Financial Year 2025-26...
26 Sep, 2025 | 10:48am • Source: BSE
Glenmark Strengthens Oncology Portfolio with Hengrui''s HER2 Targeting ADC for Multiple Regions
24 Sep, 2025 | 03:39pm • Source: BSE
Revised record date for payment of interim dividend, if declared, will be Friday, October 03, 2025.
22 Sep, 2025 | 05:40pm • Source: BSE
Record date for payment of Interim Dividend, if declared, will be Tuesday, September 30, 2025.
22 Sep, 2025 | 04:11pm • Source: BSE
Glenmark Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/09/2025 ,inter alia, to consider and...
22 Sep, 2025 | 04:06pm • Source: BSE
Glenmark Pharmaceuticals Limited has informed the Exchange about Credit Rating
19 Sep, 2025 | 10:36am • Source: NSE
Kindly find enclosed rating rationale issued by CRISIL Ratings for your reference.
19 Sep, 2025 | 10:29am • Source: BSE
Further to the earlier intimation dated August 14, 2025, we hereby advise that a Business Transfer Agreement for transfer of the Company''s Consumer Care Business...
15 Sep, 2025 | 05:22pm • Source: BSE
Glenmark Pharmaceuticals Limited has informed the Exchange about General Updates
09 Sep, 2025 | 09:51am • Source: NSE
Intimation regarding upfront payment received
09 Sep, 2025 | 08:53am • Source: BSE
Please find attached details of Analyst / Institutional Investor Meet
08 Sep, 2025 | 08:11pm • Source: BSE
Glenmark initiates a Multi-Country Phase 3 Clinical Trial for Envafolimab in Resectable Stage III Non-Small Cell Lung Cancer
05 Sep, 2025 | 09:48am • Source: BSE
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated September 02, 2025, titled "Glenmark Pharmaceuticals Inc., USA to launch Eribulin Mesylate Injection,...
02 Sep, 2025 | 10:42am • Source: NSE
Glenmark Pharmaceuticals Inc., USA to launch Eribulin Mesylate Injection, 1mg/2Ml (0.5 mg/mL) Single-Dose Vials
02 Sep, 2025 | 10:27am • Source: BSE
Please find enclosed copy of newspaper advertisement published in Financial Express (English) and Loksatta (Marathi)
01 Sep, 2025 | 05:58pm • Source: BSE